0.3598

4.59% 0.0158

Werewolf Therapeutics Inc (HOWL)

Overview News Price History Option Chain Financials Discussions Forecast

Werewolf Therapeutics Inc stock is traded at $0.3598, with a volume of 590.80K. It is up +4.59% in the last 24 hours and down -5.79% over the past month. Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.

Previous Close:

$0.344

Open:

$0.32

24h Volume:

590.80K

Relative Volume:

0.95

Market Cap:

$17.49M

Revenue:

$1.14M

Net Income/Loss:

$-56.27M

P/E Ratio:

-0.2964

EPS:

-1.2139

Net Cash Flow:

$-51.94M

1W Performance:

+1.93%

1M Performance:

-5.79%

6M Performance:

-42.92%

1Y Performance:

-66.06%

1-Day Range:

$0.32

$0.3613

1-Week Range:

$0.295

$0.37

52-Week Range:

$0.27

$2.38

Werewolf Therapeutics Inc Stock (HOWL) Company Profile

Name

Werewolf Therapeutics Inc

Sector

Healthcare (1094)

Industry

Biotechnology (614)

Phone

617-952-0555

Address

200 TALCOTT AVENUE, WATERTOWN

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

HOWL's Discussions on Twitter

Compare HOWL vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HOWL Werewolf Therapeutics Inc	0.3598	16.72M	1.14M	-56.27M	-51.94M	-1.2139
VRTX Vertex Pharmaceuticals Inc	498.43	132.55B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	662.88	70.90B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	915.30	57.21B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	323.50	42.94B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.77	40.49B	742.00K	-1.37B	-1.07B	-7.0731

Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-25	Downgrade	Wedbush	Outperform → Neutral
Apr-03-24	Initiated	JMP Securities	Mkt Outperform
Aug-24-23	Initiated	Wedbush	Outperform
Jun-06-23	Resumed	Jefferies	Buy
Sep-10-21	Initiated	BofA Securities	Buy
May-25-21	Initiated	Evercore ISI	Outperform
May-25-21	Initiated	H.C. Wainwright	Buy
May-25-21	Initiated	Jefferies	Buy
May-25-21	Initiated	SVB Leerink	Outperform

View All

Werewolf Therapeutics Inc Stock (HOWL) Latest News

Jul 08, 2026

Werewolf Therapeutics director Luke Evnin sells $44,749 in stock - Investing.com

Jul 08, 2026

Form 4 Werewolf Therapeutics Inc For: 8 July By Investing.com - Investing.com Canada

Jul 08, 2026

Werewolf Therapeutics director Luke Evnin sells $44,749 in stock By Investing.com - Investing.com Canada

Jul 08, 2026

Werewolf Therapeutics (HOWL) director-linked funds sell 143,199 shares - Stock Titan

Jul 08, 2026

Jul 07, 2026

Werewolf Therapeutics outlines its immuno-oncology strategy as Nasdaq-listed biotech - Ad-hoc-news.de

Jul 07, 2026

Jul 06, 2026

[144] Werewolf Therapeutics, Inc. SEC Filing - Stock Titan

Jul 06, 2026

Jul 02, 2026

RA Capital trims Werewolf Therapeutics (HOWL) stake below 5% threshold - Stock Titan

Jul 02, 2026

Form 13D/A WEREWOLF THERAPEUTICS For: 2 July By Investing.com - Investing.com South Africa

Jul 02, 2026

Werewolf Therapeutics (HOWL) price target increased by 20.19% to 6.38 - MSN

Jul 02, 2026

Jul 01, 2026

Werewolf Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView

Jul 01, 2026

Jun 29, 2026

Werewolf Therapeutics director Luke Evnin sells $47,125 in stock By Investing.com - Investing.com South Africa

Jun 29, 2026

Form 4 Werewolf Therapeutics Inc For: 29 June By Investing.com - Investing.com South Africa

Jun 29, 2026

Form 144 Werewolf Therapeutics For: 29 June By Investing.com - Investing.com South Africa

Jun 29, 2026

Werewolf Therapeutics director Luke Evnin sells $47,125 in stock - Investing.com

Jun 29, 2026

Entities tied to Werewolf Therapeutics (HOWL) director Luke Evnin sell 157K shares - Stock Titan

Jun 29, 2026

Jun 27, 2026

Werewolf Therapeutics, Inc. Actuals & Estimates (NASDAQ:HOWL) - TradingView

Jun 27, 2026

Form 13D/A WEREWOLF THERAPEUTICS For: 26 June By Investing.com - Investing.com South Africa

Jun 27, 2026